Jounce Therapeutics
1030 Massachusetts Avenue
Cambridge
Massachusetts
02138
United States
Tel: 857-259-3840
Fax: 617-812-5345
Website: http://www.jouncetx.com/
About Jounce Therapeutics
Jounce Therapeutics is focused on the discovery and development of novel cancer immunotherapies designed to work not by treating a patient's tumor directly, but instead by harnessing the patient's immune system to seek out and attack cancerous cells and tumors.
This transformational approach has the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life.
Jounce is building upon the unparalleled expertise of its renowned scientific founders – world leaders in the fields of immunology, cancer biology and clinical and translational medicine in cancer – and its increasing understanding of how cancer cells communicate and interact with the immune system to position the company at the forefront of cancer immunotherapy drug discovery and development.
Based in Cambridge, Mass., Jounce is a private company launched in 2013 with $47 million in Series A venture capital financing by Third Rock Ventures.
111 articles with Jounce Therapeutics
-
Jounce Therapeutics Reports Third Quarter 2017 Financial Results
11/13/2017
Jounce has narrowed its financial guidance previously provided for the full year 2017.
-
Jounce Therapeutics to Announce Third Quarter 2017 Financial Results and Host Conference Call on Monday, November 13, 2017
11/8/2017
Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 8:00 a.m. ET.
-
Jounce Therapeutics Appoints Luis A. Diaz, Jr., M.D., to its Board of Directors
10/23/2017
Dr. Diaz brings to the company his world-renowned expertise in cancer genetics and a precision medicine approach to immuno-oncology.
-
Jounce Names Ex-Ariad's Top Dealmaker as Its New CBO
8/16/2017
-
Jounce Reports Second Quarter 2017 Financial Results
8/9/2017
-
Jounce To Announce Second Quarter 2017 Financial Results And Host Conference Call On Wednesday, August 9, 2017
8/2/2017
-
OncoSec Medical Announces Technology Access Program Agreement With Jounce
6/12/2017
-
Jounce Presents Phase I Data From ICONIC Study Of JTX-2011 In Patients With Advanced Solid Tumors At 2017 ASCO Annual Meeting
6/5/2017
-
Jounce's Number One Employee Rejoins Constellation Pharma as New CEO
5/26/2017
-
Jounce To Present Phase I Data From JTX-2011 ICONIC Trial At 2017 ASCO Annual Meeting
5/18/2017
-
Jounce Reports First Quarter 2017 Financial Results
5/9/2017
-
Jounce Initiates Phase II Portion Of ICONIC Study Of JTX-2011 In Patients With Advanced Solid Tumors
4/21/2017
-
Cambridge Biotech Jounce Bounces on the IPO Scene, Raises $102 Million
1/27/2017
-
Cambridge-Based Jounce Files for $75 Million IPO
1/3/2017
-
Jounce Appoints Stephen Farrand, Ph.D., To Chief Technical Officer
9/26/2016
-
Cambridge Startup Jounce Lands $2.5 Billion Deal With Biotech's Best Friend Celgene
7/20/2016
-
Adimab LLC. Announces Two New Partnerships And Commercial Licenses With Eli Lilly, Kite Pharma And Jounce
4/27/2016
-
Jounce Presents Data Highlighting Advances From Two Programs In Its Immuno-Oncology Pipeline At The 2016 AACR Annual Meeting
4/18/2016
-
Jounce Announces Presentation At Society For Immunotherapy Of Cancer’s 30th Annual Meeting
11/4/2015
-
Jounce Appoints Elizabeth Trehu, M.D., To Chief Medical Officer
11/3/2015